<DOC>
	<DOCNO>NCT00051701</DOCNO>
	<brief_summary>The purpose study determine optimal dose Campath patient relapse refractory ( failed standard therapy ) non-Hodgkin 's lymphoma . The study also evaluate safety drug whether effective treating patient .</brief_summary>
	<brief_title>Phase I/II Study CAMPATH Patients With Relapsing Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This study conduct 2 part primary objective part 1 determine maximum tolerate dose ( MTD ) CAMPATH ( alemtuzumab , MABCAMPATH , CAMPATH ) administer intravenously ( IV ) week treatment relapse refractory non-Hodgkin 's lymphoma ( NHL ) . The primary objective part 2 determine overall response rate ( complete response , CR/unconfirmed , plus partial response ) weekly IV CAMPATH treatment relapse refractory NHL . This Phase I/II study , open-label , multicenter study evaluate efficacy safety weekly IV CAMPATH therapy patient relapse refractory non-Hodgkin 's lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patients must : Pathologically confirm diagnosis relapse refractory nonHodgkin 's lymphoma fail conventional therapy . Measurable disease ( lesion accurately measure CT scan great transverse diameter large equal 1 cm palpable lesion diameter large equal 2 cm ) . Life expectancy least 12 week . World Health Organization ( WHO ) performance status ( PS ) 0 , 1 , 2 . Adequate marrow organ function ( detail list protocol ) . Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment . Male female patient must agree use effective contraceptive method study treatment , appropriate , minimum 6 month follow study therapy . Signed , write informed consent . Patients must : Prior autologous bone marrow stem cell transplant within 6 month study entry . A history prior allogeneic bone marrow transplant organ transplant . Previously untreated nonHodgkin 's lymphoma . Previously treat CAMPATH . Patients bulky disease , ie single mass &gt; 7.5cm . Prior radiotherapy site measurable disease . Medical condition require chronic use oral , highdose corticosteroid . Autoimmune thrombocytopenia . Use investigational agent within previous 30 day anticancer therapy within previous 3 week . Patients must recover acute toxicity prior therapy . Past history anaphylaxis follow exposure humanize monoclonal antibody . Active , uncontrolled infection , include human immunodeficiency virus ( HIV ) positive . Active secondary malignancy . Active central nervous system ( CNS ) involvement NHL . Pregnant lactate woman . Male female patient agree use effective contraceptive method ( ) study . Any significant concurrent disease illness would , opinion investigator , compromise patient safety compliance , interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Non-Hodgkins lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Campath</keyword>
	<keyword>alemtuzumab</keyword>
</DOC>